22P: Effects of datopotamab deruxtecan (Dato-DXd) vs docetaxel on patient-reported outcomes (PROs) in adults with previously treated advanced or metastatic non squamous (NSQ) non-small cell lung cancer (NSCLC): Results from TROPION-LUNG01 | Publicación